Global Respiratory Inhalers Market, by Product Type (Dry Powder Inhalers, Metered Dose Inhalers and Nebulizers), by Application (Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Arterial Hypertension and Cystic Fibrosis), by Technology (Digital and Manual), and by Region - Trends and Analysis to 2025

Respiratory Inhalers – Getting the Wind Back in Your Lungs

Respiratory diseases such as bronchitis, asthma, allergic rhinitis, pneumonia and sinusitis can significantly curtail the physical activities of the individual. The symptoms associated with both mild and severe manifestations of these respiratory conditions include coughing, wheezing, chest pain, respiratory distress, shortness of breath, congestion, and even death in severe cases. These conditions lead to substantial morbidity and causes large cost of burden to the society. Increasing air pollution can severely affect respiratory health of children as well as adults. Various studies conducted have shown the ill effects of air pollution that can exacerbate existing respiratory conditions such as asthma, COPD, and upper airway allergies. According to the Forum of International Respiratory Societies, in 2013, young children and infants were especially susceptible to respiratory diseases. Around 9.0 million children under the age of 5 years die per year and the common thing in them is the presence of lung diseases. Increase in evidences through such studies suggests that the exposure to certain type of air pollutants contributes to the onset of asthma. However, studies related to the exacerbation of pre-acquired and existing asthma are more prevalent as they provide favorable conditions to study.

The global respiratory inhalers market was valued at US$ 27,424.4 million in 2016 and is expected to witness a robust CAGR of 5.7% over the forecast period (2017-2025).

Figure 1. Global Respiratory Inhalers Market Size and Forecast, US$ Million and Y-o-Y Growth (%), 2015–2025

respiratory inhalers market

Source: Coherent Market Insights Analysis (2017)

Generic Respiratory Inhalers are expected to be Major Revenue Generators for Market Players

According to Next Breath, LLC, in 2013, in the U.S for asthma/COPD there were no generic inhalers available, which includes both categories of standard asthma treatment such as controller medications for long-term prevention and rescue medication for quick relief. The above inhalers medicine average cost ranges between US$ 35 and US$ 300, rendering the treatment expensive for both consumers that are insured as well as uninsured. Furthermore, there are various many pressurized metered dose inhalers (pMDIs) that are approaching towards the patent expiration, and due to the lack of a document from the U.S. Food and Drug Administration (FDA) for guidance, generic companies are reluctant to spend in new product development, which finally might not be acceptable to the agency. According to Forum of International Respiratory Societies, in 2013, it has been estimated that around 235 million people suffered from asthma and more than 200 million people were affected from chronic obstructive pulmonary disease (COPD), and around 65 million endure mild-to-severe COPD. Also, around 2 billion people were exposed to the toxic effects of biomass fuel consumption and air pollution and by tobacco smoke.

Growth in respiratory inhalers market on the backdrop of product launches and Technological Advancements

For instance:

  • In 2017, Cipla launched Synchrobreathe, a revolutionary inhaler that will bring great relief to millions of South Africans with obstructive airway diseases (OAD) such as asthma
  • Smart inhalers have embedded sensors with bluetooth technology. These devices also come up with touchscreens, audio visual medication reminders along with additional advantages such as mobile application connectivity, customized user interface options, real time analysis through cloud based portals through researchers and clinicians. In September, 2017, Adherium received approval from the U.S Food and Drug Administration (FDA) for its SmartTouch inhaler monitoring device to be used with AstraZeneca’s Symbiocort aerosol inhaler.
  • In October, 2017, United Therapeutics Corporation received U.S. FDA approval for a new inhalation device TD-300/A, for the use with Tyvaso (treprostinil) inhalation solution to treat patient with pulmonary arterial hypertension. The device aid patient compliance and provides ease of use.  It will also reduce the rate of therapy discontinuation associated with the current nebulizer.
  • In September, GlaxoSmithKline plc, received approval for Trelegy Ellipta. Trelegy Ellipta, is the first once-daily use inhaler triple therapy (i.e. combination of 3 active molecules in a single inhaler) for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
  • In April, 2016, AstraZeneca received approval for Bevespi Aerosphere, the first product which uses AstraZeneca’s Co-Suspension Technology. The technology enables more than one medicine delivery from a single MDI.
  • In 2010, around 115,000 patients were hospitalized due to sever chronic obstructive pulmonary disease, which cost the NHS around US$ 367.85 Mn and is expected to increase over the forecast period. Sandoz launched an innovative respiratory inhaler AirFluSal Forspiro in the UK in 2015, to capitalize on the highly lucrative market in the region.

Increasing number of research collaborations is expected to improve the time-to-market of highly effective and advanced products. Some of the major players involved in global respiratory inhalers market are AstraZeneca, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc, Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding and Teva Pharmaceutical Industries Ltd.

Chronic respiratory diseases are the group of chronic diseases which affect airways, lungs and the other parts of respiratory system. Chronic respiratory disease include asthma and respiratory allergies, Chronic Obstructive Pulmonary Disease (COPD), Occupational Lung Diseases, Sleep Apnea Syndrome and Pulmonary Hypertension. However 70% chronic respiratory disease are asthma and chronic obstructive pulmonary disease. In 2012, globally, 1 billion people are affected with chronic respiratory disease and account for 7% of all global deaths with addition 1.4 million lung cancer deaths annually. Tuberculosis is considered as one of the communicable lung disease and in 2012, 1.3 million people died of tuberculosis and 8.6 million new cases were yet to be treated.

The respiratory inhalers market is expected to gain steady traction in the foreseeable future as the product is available in various designs and can be used by any age group individual. Manufacturers are focused on reducing production costs and increasing profitability to sustain the market demand.

Market Dynamics

Factors such as rising prevalence of asthma, chronic obstructive respiratory disease and other respiratory diseases propel the respiratory inhalers market globally. However, drawbacks such as lack of a single effective inhaler devices, adverse effects and difficulties faced during drug inhalation, lack of skilled pulmonologist, higher price of inhaler devices are factors hindering respiratory inhalers market growth.

People suffering from respiratory disorders are now switching towards combinational therapies which is associated with benefits such as increased efficacy and easy reimbursement policies. Opting for combination therapies becomes tough for the individuals who have complex indications of respiratory disease. High preference of combination therapies such as triple combination therapy for chronic obstructive pulmonary disease (COPD) patients is expected to drive growth of the global respiratory inhaler market over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the respiratory inhalers and is its application, market size (US$ Million) and Cumulative Annual Growth Rate (CAGR (%)) for the forecast period: 2016 – 2024, considering 2015 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global respiratory inhalers market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
  • Key companies covered as a part of this study include AstraZeneca, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim GmbH, Cipla Ltd., GlaxoSmithKline plc, Koninklijke Philips N.V., Merck & Co., Inc., OMRON Healthcare Europe B.V., PARI Medical Holding and Teva Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, end user upgrades, market expansion, and marketing tactics
  • The global respiratory inhalers market report caters to various stakeholders in this industry, including investors, drug/product manufacturers, distributors and suppliers for respiratory inhalers, research and consulting firms, new entrants, and financial analysts
  • Various strategy matrices used in analyzing the respiratory inhalers market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

  • Global Respiratory Inhalers Market, By Product Type:
    • Dry Powder Inhalers
      • Single Unit Dose
      • Multi Dose
      • Multi-Unit Dose
    • Metered Dose Inhalers
    • Nebulizers
      • Compressed
      • Mesh
      • Ultrasonic
  • Global Respiratory Inhalers Market, By Application:
    • Asthma
    • Chronic Obstructive Pulmonary Disease
    • Pulmonary Arterial Hypertension
    • Cystic Fibrosis
  • Global Respiratory Inhalers Market, By Technology:
    • Digital
    • Manual
  • Global Respiratory Inhalers Market, By Geography:
    • North America,
      • By Product Type:
        • Dry Powder Inhalers
          • Single Unit Dose
          • Multi Dose
          • Multi-Unit Dose
        • Metered Dose Inhalers
        • Nebulizers
          • Compressed
          • Mesh
          • Ultrasonic
      • By Application:
        • Asthma
        • Chronic Obstructive Pulmonary Disease
        • Pulmonary Arterial Hypertension
        • Cystic Fibrosis
      • By Technology
        • Digital
        • Manual
      • By Country
        • U.S.
        • Canada
    • Europe
      • By Product Type:
        • Dry Powder Inhalers
          • Single Unit Dose
          • Multi Dose
          • Multi-Unit Dose
        • Metered Dose Inhalers
        • Nebulizers
          • Compressed
          • Mesh
          • Ultrasonic
      • By Application:
        • Asthma
        • Chronic Obstructive Pulmonary Disease
        • Pulmonary Arterial Hypertension
        • Cystic Fibrosis
      • By Technology
        • Digital
        • Manual
      • By Country
        • U.K.
        • Germany
        • Italy
        • France
        • Russia
        • Spain
        • Rest of Europe
    • Asia Pacific
      • By Product Type:
        • Dry Powder Inhalers
          • Single Unit Dose
          • Multi Dose
          • Multi-Unit Dose
        • Metered Dose Inhalers
        • Nebulizers
          • Compressed
          • Mesh
          • Ultrasonic
      • By Application:
        • Asthma
        • Chronic Obstructive Pulmonary Disease
        • Pulmonary Arterial Hypertension
        • Cystic Fibrosis
      • By Technology
        • Digital
        • Manual
      • By Country
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Product Type:
        • Dry Powder Inhalers
          • Single Unit Dose
          • Multi Dose
          • Multi-Unit Dose
        • Metered Dose Inhalers
        • Nebulizers
          • Compressed
          • Mesh
          • Ultrasonic
      • By Application:
        • Asthma
        • Chronic Obstructive Pulmonary Disease
        • Pulmonary Arterial Hypertension
        • Cystic Fibrosis
      • By Technology
        • Digital
        • Manual
      • By Country
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East
      • By Product Type:
        • Dry Powder Inhalers
          • Single Unit Dose
          • Multi Dose
          • Multi-Unit Dose
        • Metered Dose Inhalers
        • Nebulizers
          • Compressed
          • Mesh
          • Ultrasonic
      • By Application:
        • Asthma
        • Chronic Obstructive Pulmonary Disease
        • Pulmonary Arterial Hypertension
        • Cystic Fibrosis
      • By Technology
        • Digital
        • Manual
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type:
        • Dry Powder Inhalers
          • Single Unit Dose
          • Multi Dose
          • Multi-Unit Dose
        • Metered Dose Inhalers
        • Nebulizers
          • Compressed
          • Mesh
          • Ultrasonic
      • By Application:
        • Asthma
        • Chronic Obstructive Pulmonary Disease
        • Pulmonary Arterial Hypertension
        • Cystic Fibrosis
      • By Technology
        • Digital
        • Manual
      • By Country
        • North Africa
        • Central Africa
        • South Africa
  • Company Profiles
    • AstraZeneca Plc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
      • Future Plans
    • Beximco Pharmaceuticals Ltd.
    • Boehringer Ingelheim GmbH
    • Cipla Ltd.
    • GlaxoSmithKline Plc.
    • Koninklijke Philips N.V.
    • Merck & Co. Inc.
    • Omron Healthcare Europe B.V.
    • PARI Medical Holding
    • Teva Pharmaceutical Industries Ltd.
    • H&T PRESSPART

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet By Devices
      • Market Snippet By Technology
      • Market Snippet By Therapeutic Application
      • Market Snippet By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Challenges
      • Market Opportunities
    • Regulatory Scenario
    • Industry Trend
    • Epidemiology
    • Merger and Acquisitions
    • New Product Approvals/Launch
    • Promotion and Marketing Initiatives
  4. Global Respiratory Inhalers Market, By Devices, 2015 - 2025 (US$ Million)
    • Introduction
      • Market Share Analysis, 2017 and 2025 (%)
      • Y-O-Y Growth Analysis, 2015 - 2025
      • Segment Trends
    • Nebulizers
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
      • Compressed
        • Introduction
        • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
      • Mesh
        • Introduction
        • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
      • Ultrasonic
        • Introduction
        • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
    • Dry Powder Inhaler
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
      • Single Unit Dose Inhaler
        • Introduction
        • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
      • Multi Dose Inhaler
        • Introduction
        • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
      • Multi-Unit Dose Inhaler
        • Introduction
        • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
    • Metered Dose Inhaler
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
  5. Global Respiratory Inhalers Market, By Technology, 2015 - 2025 (US$ Million)
    • Introduction
      • Market Share Analysis, 2017 and 2025 (%)
      • Y-O-Y Growth Analysis, 2015 - 2025
      • Segment Trends
    • Digital
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
    • Manual
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
  6. Global Respiratory Inhalers Market, By Therapeutic Application, 2015 - 2025 (US$ Million)
    • Introduction
      • Market Share Analysis, 2017 and 2025 (%)
      • Y-O-Y Growth Analysis, 2015 - 2025
      • Segment Trends
    • Asthma
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
    • Chronic Obstructive Pulmonary Disease
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
    • Pulmonary Arterial Hypertension
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
    • Cystic Fibrosis
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
  7. Global Respiratory Inhalers Market, By Regions, 2015 - 2025 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2017 and 2025 (%)
      • Y-O-Y Growth Analysis, For Regions, 2015 - 2025
    • North America
      • Regional Trends
      • Market Size and Forecast, By Devices, 2015 - 2025 (US$ Million)
      • Market Size and Forecast, By Technology, 2015 - 2025 (US$ Million)
      • Market Size and Forecast, By Therapeutic Application, 2015 - 2025 (US$ Million)
      • Market Size and Forecast, By Country, 2015 - 2025 (US$ Million)
        • U.S.
    • Europe
      • Regional Trends
      • Market Size and Forecast, By Devices, 2015 - 2025 (US$ Million)
      • Market Size and Forecast, By Technology, 2015 - 2025 (US$ Million)
      • Market Size and Forecast, By Therapeutic Application, 2015 - 2025 (US$ Million)
      • Market Size and Forecast, By Country, 2015 - 2025 (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Regional Trends
      • Market Size and Forecast, By Devices, 2015 - 2025 (US$ Million)
      • Market Size and Forecast, By Technology, 2015 - 2025 (US$ Million)
      • Market Size and Forecast, By Therapeutic Application, 2015 - 2025 (US$ Million)
      • Market Size and Forecast, By Country, 2015 - 2025 (US$ Million)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Regional Trends
      • Market Size and Forecast, By Devices, 2015 - 2025 (US$ Million)
      • Market Size and Forecast, By Technology, 2015 - 2025 (US$ Million)
      • Market Size and Forecast, By Therapeutic Application, 2015 - 2025 (US$ Million)
      • Market Size and Forecast, By Country, 2015 - 2025 (US$ Million)
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East
      • Regional Trends
      • Market Size and Forecast, By Devices, 2015 - 2025 (US$ Million)
      • Market Size and Forecast, By Technology, 2015 - 2025 (US$ Million)
      • Market Size and Forecast, By Therapeutic Application, 2015 - 2025 (US$ Million)
      • Market Size and Forecast, By Country, 2015 - 2025 (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Regional Trends
      • Market Size and Forecast, By Devices, 2015 - 2025 (US$ Million)
      • Market Size and Forecast, By Technology, 2015 - 2025 (US$ Million)
      • Market Size and Forecast, By Therapeutic Application, 2015 - 2025 (US$ Million)
      • Market Size and Forecast, By Country, 2015 - 2025 (US$ Million)
        • Northern Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • AstraZeneca plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Beximco Pharmaceuticals Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Boehringer Ingelheim GmbH
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Cipla Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • GlaxoSmithKline plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Koninklijke Philips N.V.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Merck & Co., Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • OMRON Healthcare Europe B.V.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • PARI Medical Holding
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • Teva Pharmaceutical Industries Ltd
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
      • H&T PRESSPART
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 25 market data tables and 35 figures on "Respiratory Inhalers Market - Global forecast to 2025”

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.